Figure 3.

A 64-years old man with diagnosis of prostate adenocarcinoma previously treated through robot-assisted radical prostatectomy and pelvic lymph-node dissection in 2016 (pT2apN0c; Gleason score 4 + 3) came to our attention in February 2022 for biochemical recurrence (PSA value: 0.64 ng/mL) and underwent ¹⁸F-PSMA-1007 PET/CT. PET/CT scan was performed 90 min after 250 MBq ¹⁸F-PSMA-1007 administration. PET/CT images did not show any sign of suspect local recurrence nor distant metastases distinctly attributable to prostate cancer. Nevertheless, in the upper abdomen sections ((A) fused PET/CT axial, (B) fused PET/CT coronal, (C) fused PET/CT sagittal, (D) low-dose CT axial, (E) low-dose CT coronal; (F): low-dose CT sagittal), an area of abnormal and intense ¹⁸F-PSMA-1007 uptake was observed in an exophitic lesion located at the lower pole of the left kidney (white arrow). After routine diagnostic work up, the patient was submitted to total nephrectomy and histologic examination was consistent with the diagnosis of ccRCC.